Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2335-2341

  Eron Jr , Joseph J ^a,i   Park, Jeong Gun ^b   Haubrich, Richard ^c   Aweeka, Francesca ^d   Bastow, Barbara ^e   Pakes, Gary E ^f   Yu, Song ^b   Wu, Hulin ^g   Richman, Douglas D ^c,h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ENFUVIRTIDE; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LABORATORY TEST; MALE; MULTICENTER STUDY; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AREA UNDER CURVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RITONAVIR; RNA, VIRAL;

EID: 67149097953     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01387-08     Document Type: Article

References (28)

1. Acosta, E. P., H. Wu, S. M. Hammer, S. Yu, D. R. Kuritzkes, A. Walawander, J. J. Eron, C. J. Fichtenbaum, C. Pettinelli, D. Neath, E. Ferguson, A. J. Saah, and J. G. Gerber. 2004. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 37:1358-1366.
2. Anderson, P. L., R. C. Brundage, L. Bushman, T. N. Kakuda, R. P. Remmel, and C. V. Fletcher. 2000. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 14:2293-2297.
3. Barrail, A., C. Le Tiec, S. Paci-Bonaventure, V. Furlan, I. Vincent, and A. M. Taburet. 2006. Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration. Ther. Drug Monit. 28:89-94.
4. Barrail-Tran A., L. Morand-Joubert, G. Poizat, G. Raguin, C. Le Tiec, F. Clavel, E. Dam, G. Chêne, P. M. Girard, A. M. Taburet, and the Puzzle-1 (ANRS 104) Study Group. 2008. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrob. Agents Chemother. 52:1642-1646.
5. Boffito, M., E. Acosta, D. Burger, C. V. Fletcher, C. Flexner, R. Garaffo, G. Gatti, M. Kurowski, C. F. Perno, G. Peytavin, M. Regazzi, and D. Back. 2005. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir. Ther. 10:375-392.
6. Boffito, M., P. G. Hoggard, W. E. Lindup, S. Bonora, A. Sinicco, S. H. Khoo, G. Di Perri, and D. J. Back. 2004. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther. Drug Monit. 26:35-39.
7. Clevenbergh, P., R. Boulme, M. Kirstetter, and P. Dellamonica. 2004. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med. 5:284-288. (Pubitemid 39077121)
8. Clotet, B., N. Bellos, J. M. Molina, D. Cooper, J. C. Goffard, A. Lazzarin, A. Wohrmann, C. Katlama, T. Wilkin, R. Haubrich, C. Cohen, C. Farthing, D. Jayaweera, M. Markowitz, P. Ruane, S. Spinosa-Guzman, and E. Lefebvre. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178. (Pubitemid 46541620)
9. Corbett, A. H., M. L. Lim, and A. D. Kashuba. 2002. Kaletra (lopinavir/ritonavir). Ann. Pharmacother. 36:1193-1203. (Pubitemid 34755798)
10. Duval, X., C. Lamotte, E. Race, D. Descamps, F. Damond, F. Clavel, C. Leport, G. Peytavin, and J. L. Vilde. 2002. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob. Agents Chemother. 46:570-574.
11. Grinsztejn, B., B. Y. Nguyen, C. Katlama, J. M. Gatell, A. Lazzarin, D. Vittecoq, C. J. Gonzalez, J. Chen, C. M. Harvey, and R. D. Isaacs. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. (Pubitemid 46553846)
12. Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV- 1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475. (Pubitemid 44142769)
13. Hoefnagel, J. G., P. P. Koopmans, D. M. Burger, R. Schuurman, and J. M. Galama. 2005. Role of the inhibitory quotient in HIV therapy. Antivir. Ther. 10:879-892.
14. Hoefnagel, J. G., M. J. van der Lee, P. P. Koopmans, R. Schuurman, S. Jurriaans, A. I. van Sighem, L. Gras, F. de Wolf, J. M. Galama, and D. M. Burger. 2006. The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. AIDS 20:1069-1071.
15. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
16. 15a. Hsu, A., R. Bertz, D. Hickman, M. Emery, G. Kumar, J. Denissen, S. Vasavanonda, A. Molla, D. Kempf, G. R. Granneman, and E. Sun. 2001. 8th Conf. Retrovir. Opportunistic Infect., abstr. 753.
17. Khoo, S. H., A. Winston, and D. Back. 2007. Combining resistance and pharmacology for optimum patient care. Curr. Opin. HIV AIDS 2:157-168.
18. Lazzarin, A., T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, J. Vingerhoets, G. de Smedt, B. Baeten, G. Beets, R. Sinha, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39-48. (Pubitemid 47017467)
19. 17a. Limoli, K., L. Trinh, G. Heilek-Snyder, N. Hellmann, and C. Petropoulos. 2002. 14th Int. AIDS Conf., abstr. TuPeB4574.
20. Livington, D. J., S. Pazhanisamy, D. J. Porter, J. A. Partaledis, R. D. Tung, and G. R. Painter. 1995. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172:1238-1245.
21. Madruga, J. V., P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, J. Vingerhoets, G. de Smedt, L. Leopold, R. Trefiglio, and B. Woodfall. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:29-38. (Pubitemid 47017466)
22. Marcelin, A. G., I. Cohen-Codar, M. S. King, P. Colson, E. Guillevic, D. Descamps, C. Lamotte, V. Schneider, J. Ritter, M. Segondy, H. Peigue-Lafeuille, L. Morand-Joubert, A. Schmuck, A. Ruffault, P. Palmer, M. L. Chaix, V. Mackiewicz, V. Brodard, J. Izopet, J. Cottalorda, E. Kohli, J. P. Chauvin, D. J. Kempf, G. Peytavin, and V. Calvez. 2005. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 49:1720-1726.
23. Marcelin, A. G., C. Lamotte, C. Delaugerre, N. Ktorza, H. Ait Mohand, R. Cacace, M. Bonmarchand, M. Wirden, A. Simon, P. Bossi, F. Bricaire, D. Costagliola, C. Katlama, G. Peytavin, and V. Calvez. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47:594-600.
24. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262. (Pubitemid 28489625)
25. Pellegrin, I., D. Breilh, G. Coureau, S. Boucher, D. Neau, P. Merel, D. Lacoste, H. Fleury, M. C. Saux, J. L. Pellegrin, E. Lazaro, F. Dabis, and R. Thiebaut. 2007. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob. Agents Chemother. 51:1473-1480.
26. 1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 45:852-856.
27. Shelton, M. J., M. B. Wire, Y. Lou, B. Adamkiewicz, and S. S. Min. 2006. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob. Agents Chemother. 50:928-934.
28. Valer, L., D. Gonzalez de Requena, C. de Mendoza, L. Martin-Carbonero, J. Gonzalez-Lahoz, and V. Soriano. 2004. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens. AIDS Patient Care STD 18:1-6. (Pubitemid 38435506)